Mitsubishi UFJ Morgan Stanley Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$78K	Sell	420 -550	-57%	-$102K	0.16%	27
2014 Q3	$161K	Sell	970 -300	-24%	-$49.3K	0.46%	16
2014 Q2	$198K	Sell	1,270 -110	-8%	-$17.4K	0.58%	12
2014 Q1	$210K	Hold	1,380	–	–	0.56%	8
2013 Q4	$183K	Hold	1,380	–	–	0.3%	14
2013 Q3	$160K	Hold	1,380	–	–	0.26%	13
2013 Q2	$127K	Buy	+1,380	New	+$133K	0.42%	17

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's ALXN Position: Q4 2014 in Review

Mitsubishi UFJ Morgan Stanley Securities reduced its Alexion Pharmaceuticals (ALXN) stake by 57% in Q4 2014, selling an estimated $102K and leaving 420 shares worth $78K. The position accounts for 0.16% of the portfolio, ranked #27.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in ALXN in Q2 2013 and has held it in 7 quarters since. The position peaked at $210K in Q1 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

Mitsubishi UFJ Morgan Stanley Securities held 420 shares of Alexion Pharmaceuticals worth $78K as of Q4 2014.
Mitsubishi UFJ Morgan Stanley Securities sold 550 Alexion Pharmaceuticals shares in Q4 2014, an estimated $102K.
Alexion Pharmaceuticals made up 0.16% of Mitsubishi UFJ Morgan Stanley Securities's portfolio in Q4 2014, its #27 holding.
Mitsubishi UFJ Morgan Stanley Securities first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
Mitsubishi UFJ Morgan Stanley Securities's Alexion Pharmaceuticals position peaked at $210K in Q1 2014.
579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q4 2014, filed 17 Feb 2015.